NEW YORK (GenomeWeb News) – Molecular diagnostics firm NeuMoDx has raised $21 million in a Series B financing round to further develop its platform.

Pfizer Ventures led the round. Baird Capital, Venture Investors, and existing investors Arboretum Ventures and the Wolverine Venture Fund, which is managed by students at the University of Michigan, also participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.